Carmen Hidalgo Tenorio

CABO–CHANCE study: A real-life world study of cabotegravir plus rilpivirine long-acting intramuscular in ART-experienced people with HIV

Carmen Hidalgo Tenorio, M. Aguilera García, Ignacio de los Santos, A. Ruiz Sancho et autres

BACKGROUND: This study of people with HIV (PWH) receiving CAB + RPV LAI evaluated its effectiveness, safety, and impact on inflammatory markers, body fat/lean mass distributions, quality of life, sleep, health satisfaction, and stigma experience over 1 y. METHODS: A prospective, longitudinal, …

es (code pays fourni par la source)

Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir + Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort

David Rial‐Crestelo, Jara Llenas‐García, Carmen Hidalgo Tenorio, Jesús Troya et autres

Abstract Background The impact of pre-existing non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations (RAMs) on the effectiveness of long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) remains poorly defined, particularly for mutations like K103N that do not directly compromise RPV susceptibility (non-RPV NNRTI …

es (code pays fourni par la source)

Lack of association between loneliness, social isolation and inflammation in people living with HIV aged ≥50 years: Results from the sub-study “No One Alone-Gesida Study”

José Ramón Blanco, Helena Albendín-Iglesias, Eugenia Negredo-Puigmal, Ana Barrios-Blandino et autres

INTRODUCTION: Inflammation is linked to multiple health conditions. Emerging evidence suggest it may play a role in the association between social isolation - loneliness and health outcomes. People living with HIV (PLWH) exhibit chronic inflammation even with viral suppression, likely due to …

es (code pays fourni par la source)

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort

Luís Buzón, José Ignacio Bernardino, María Puerto, Juan Martín-Torres et autres

OBJECTIVES: Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) provides an alternative to daily therapy for people with HIV (PWH) with virologic suppression. Although genotypic testing is recommended before switching, its real-world clinical value is unclear. We assessed outcomes after switching to LAI …

es (code pays fourni par la source)

Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort

Jesús Troya, Marisa Montes, Marı́a José Galindo, Alberto Díaz-De Santiago et autres

BACKGROUND: Long-acting injectable cabotegravir and rilpivirine (LAI CAB + RPV) is an established maintenance strategy for people with HIV who are virologically suppressed, providing high efficacy and convenience in treatment. However, evidence in older adults (≥60 years), a growing and complex population, …

es (code pays fourni par la source)

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)

Sergio Serrano Villar, Laura Martín‐Pedraza, Juan Manuel Tiraboschi, Maria Teresa Novella et autres

BACKGROUND: Dual antiretroviral therapy (ART) with dolutegravir/lamivudine (DTG/3TC) is widely used in virologically suppressed individuals. However, data remain limited on potential differential effects of ART regimens on mid-term systemic inflammation and metabolic health. We evaluated whether switching from DTG/3TC to bictegravir/emtricitabine/tenofovir alafenamide …

es (code pays fourni par la source)

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysis

Gundolf Schuettfort, Jan Borch, Alfonso Cabello, María José Crusells et autres

OBJECTIVE: To investigate the efficacy and safety of first-line antiretroviral treatment (ART) with 2DR dolutegravir/lamivudine (DTG/3TC) versus 3DR bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) in persons with low CD4 cell counts and/or an AIDS-defining disease. DESIGN: Retrospective, multicentre, multinational study. METHODS: We conducted a retrospective, …

de, ee, es, pt (code pays fourni par la source)

A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

Luís Buzón, Marisa Montes, Roberto Pedrero‐Tomé, Marı́a José Galindo et autres

BACKGROUND: Daily oral antiretroviral therapy (ART) has transformed HIV into a chronic, manageable condition, but it still poses psychological, logistical, and biological challenges. Long-acting injectable (LAI) cabotegravir plus rilpivirine provides an alternative for virologically suppressed individuals, reducing treatment fatigue, stigma, and daily …

es, us (code pays fourni par la source)

Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial

Sergio Sequera, María Jesús Vivancos, Antonio Collado, Ignacio de los Santos et autres

BACKGROUND: The BICNOW clinical trial evaluated the effectiveness, safety, satisfaction, adherence to treatment, and retention in the system of a rapid initiation strategy with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in naïve HIV-infected individuals. It also assessed the burden of this infection on individuals and …

es (code pays fourni par la source)

Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead

Luís Buzón, Alfonso Cabello, Alberto Díaz de Santiago, Marı́a José Galindo et autres

Long-acting injectable cabotegravir plus rilpivirine (LAI CAB + RPV) represents an important advance in HIV treatment, offering an alternative to daily oral antiretroviral therapy (ART) for people with HIV (PWH) who are virologically suppressed. This narrative review aims to (i) evaluate the …

es (code pays fourni par la source)

Pulmonary T-cell lymphoma as a rare cause of nodular lung lesions in HIV-positive patient

Antonio Rosales‐Castillo, Antonio Bustos-Merlo, Carmen Hidalgo Tenorio

es (code pays fourni par la source)

The use of ceftobiprole in treatment pathways in Spain: An expert panel review

Carmen Hidalgo Tenorio, Francisco Javier Membrillo de Novales, Miguel Salavert, Laura Morata et autres

OBJECTIVES: Ceftobiprole is a fifth-generation β-lactam approved in Spain solely for the treatment of community- and hospital-acquired pneumonia. The objectives of this study were to discuss the use of ceftobiprole in the Spanish healthcare setting, and to review and define its positioning …

es (code pays fourni par la source)